Research programme: anti-somatostatin vaccines - Braasch BiotechAlternative Names: JH17; JH18; Somatovac®
Latest Information Update: 28 May 2013
At a glance
- Originator Braasch Biotech
- Class Peptide vaccines
- Mechanism of Action Immunomodulators; Somatostatin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Obesity
- Research Somatotropin deficiency; Type 2 diabetes mellitus